Platelet Rich Plasma in Hiatal Hernia Repair

Last updated: July 8, 2024
Sponsor: University of Southern California
Overall Status: Active - Enrolling

Phase

N/A

Condition

Hernia

Gastroesophageal Reflux Disease (Gerd)

Esophageal Disorders

Treatment

Hiatal Hernia Repair with Platelet Rich Plasma

Hiatal Hernia Repair without Platelet Rich Plasma

Clinical Study ID

NCT05023174
APP-20-05449
  • Ages > 18
  • All Genders

Study Summary

Rationale: Gastroesophageal reflux disease (GERD) is a common disease caused by a dysfunctional lower esophageal sphincter and an abnormal esophageal hiatus or hiatal hernia. Approximately 30% of large hiatal hernias will recur after surgery, in part due to weak connective tissue at the hiatus. Platelet rich plasma (PRP) is a promising autologous therapy that may address this shortcoming by substantially enhancing wound healing of the hiatus after repair.

Intervention: PRP will be applied to mesh used in hiatal hernia repair.

Objectives: The objective of this study is to determine the efficacy of PRP in hiatal hernia compared to traditional hernia repair without PRP.

Study population: 150 patients 18 years and older with large (>5cm) paraesophageal hernias.

Study methodology and study arms: a 1:1 allocation ration will be used to randomly assign 75 patients to the experimental arm (PRP with mesh) and 75 patients to the control arm (mesh only).

Study outcomes: The primary outcome will be 1-year postoperative hernia recurrence based on video esophagram and/or upper endoscopy. The secondary outcome will be GERD-Health Related Quality of Life (GERD-HRQL) scores and dysphagia scores at 6 and 12 months.

Follow-up: Patients who undergo fundoplication and hiatal hernia repair with mesh are seen in clinic for follow-up at two weeks, six weeks, six months, one year, and annually thereafter. Video esophagram or upper endoscopy will be performed at 1 year after surgery to assess the primary outcome. The investigators secondary outcome of reduction in GERD-HRQL score will be determined by a difference in the GERD-HRQL score from the preoperative score to the postoperative scores taken at 6 months and 1 year. The investigators secondary outcome of dysphagia will be determined by EAT-10 scores taken at 6 months and 1 year.

Statistics/Analysis: Descriptive statistics will be used. Intention to treat and per protocol analyses will be performed. Frequentist and Bayesian statistical analyses will be used to determine statistically and clinically important outcomes.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Documented hiatal hernia > 5cm on preoperative video esophagram or upper endoscopy

Exclusion

Exclusion Criteria:

  • Non-English speaking patients

  • Prior antireflux surgery

  • Platelet count less than 100,000

  • History of platelet dysfunction

  • Antiplatelet therapy up to ten days prior to surgery

  • Corticosteroids use up to one month before surgery

  • Diabetes

  • Active malignancy or treatment for cancer within the last year

  • Pregnancy or active breastfeeding

  • Active smoking

Study Design

Total Participants: 150
Treatment Group(s): 2
Primary Treatment: Hiatal Hernia Repair with Platelet Rich Plasma
Phase:
Study Start date:
October 18, 2021
Estimated Completion Date:
July 01, 2025

Connect with a study center

  • Keck Hospital of USC

    Los Angeles, California 90033
    United States

    Site Not Available

  • Hoag Hospital

    Newport Beach, California 92663
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.